MorphoSys AG Expected to Post FY2023 Earnings of Per Share
Slightly above 67% of MorphoSys' investor base is looking to short. The analysis of current outlook of investing in MorphoSys AG ADR suggests that many traders are alarmed regarding MorphoSys' prospects. MorphoSys' investing sentiment overview a quick insight into current market opportunities from investing in MorphoSys AG ADR. Many technical investors use MorphoSys AG ADR stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
MorphoSys |
MorphoSys AG Equities research analysts at Leerink Partnrs issued their FY2023 earnings estimates for shares of MorphoSys in a report issued on Wednesday, December 6th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings per share of for the year. Leerink Partnrs currently has a Market
Read at thelincolnianonline.com
MorphoSys Fundamental Analysis
We analyze MorphoSys' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MorphoSys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MorphoSys based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Operating Margin
Operating Margin Comparative Analysis
MorphoSys is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
MorphoSys AG ADR Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MorphoSys stock to make a market-neutral strategy. Peer analysis of MorphoSys could also be used in its relative valuation, which is a method of valuing MorphoSys by comparing valuation metrics with similar companies.
Peers
MorphoSys Related Equities
IMRX | Immuneering Corp | 6.88 | ||||
MRSN | Mersana Therapeutics | 5.63 | ||||
LYRA | Lyra Therapeutics | 5.56 | ||||
NVCT | Nuvectis Pharma | 3.98 | ||||
KRON | Kronos Bio | 2.17 | ||||
VTYX | Ventyx Biosciences | 2.15 | ||||
GOSS | Gossamer Bio | 1.19 | ||||
ACLX | Arcellx | 0.08 | ||||
MLYS | Mineralys Therapeutics, | 0.39 | ||||
PMVP | Pmv Pharmaceuticals | 0.66 | ||||
RLYB | Rallybio Corp | 1.09 | ||||
ELVN | Enliven Therapeutics | 1.50 | ||||
GLUE | Monte Rosa | 2.22 | ||||
EWTX | Edgewise Therapeutics | 3.10 | ||||
IMCR | Immunocore Holdings | 3.44 | ||||
GBIO | Generation Bio | 3.60 | ||||
IPSC | Century Therapeutics | 3.70 | ||||
REPL | Replimune | 4.14 | ||||
CCCC | C4 Therapeutics | 5.25 | ||||
PCVX | Vaxcyte | 5.61 | ||||
CGEM | Cullinan Oncology | 6.82 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in MorphoSys Stock
If you are still planning to invest in MorphoSys AG ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MorphoSys' history and understand the potential risks before investing.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |